Effect of Cross-legged Sitting Among Patients With Unilateral Hip Developmental Dysplasia

One of the most common infant developmental diseases is Hip dysplasia which is mostly seen among female' babies and leads to hip instability due to partial or full hip dislocation \[1\]. Physical therapy's role plays a significant role in treating hip dysplasia by creating new walking habits as an adaptation way and compensation for the deformity \[3\]. Focusing on the muscles that produce hip abduction force is a basic item of the hip dysplasia rehabilitation program \[4\]. Cross-legged sitting position can be considered as a common and easy position that might enhance the range of motion of the lower limb joints \[5\]. While unilateral hip developmental dysplasia has been widely distributed among newborns, especially in the last few years, the role of engaging the cross-legged sitting technique as a part of physical therapy and rehabilitation programs on improving the temporospatial parameters, muscular electrical activity and foot pressure distributing is still not clear. Therefore, this study aimed to analyze the effects of engaging the cross-legged sitting technique as a part of physical therapy and rehabilitation program among patients with UHDD by comparing the group who participated in rehabilitation program with CLS to the other without. To understand the importance of including Cross-legged sitting technique in physical therapy and rehabilitation program of Unilateral Hip Developmental Dysplasia (UHDD) to enhance the spatial and temporal measures, achieving a healthy distribution of foot pressure, increasing the electrical activity of lower limb muscles and improving the overall gait pattern. No risks at all. All instruments and techniques in this study are safe and used regularly without any hazards. The data will be stored and archived on a password-protected computer for safety and security purposes. After accomplishing the research and getting the outcomes, the results of the research may be published as an academic article in a peer-reviewed journal. In another word, no personal data will be published at all. Taking part in the study and withdrawing at any time is completely voluntary with no need to give any reason.

NCT Number	NCT07002840
Lead Sponsor	Jouf University
Conditions	Hip Developmental Dysplasia
Enrollment	16 participants
Start Date	2025-06-05
Primary Completion	2025-12-30 (estimated)
Study Completion	2025-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-04